The NAVIGATE Study: Bringing hope to those with NASH cirrhosis

The NAVIGATE clinical trial is a study clinically focused on NASH cirrhosis, for which there are no approved therapies short of a liver transplant. The NAVIGATE Study seeks to change this, offering patients and their families the first potential therapy targeted specifically at NASH cirrhosis.

A previous clinical trial showed belapectin may prevent the development of esophageal varices in patients with compensated NASH cirrhosis. Varices are an early sign for the development of serious complications in NASH cirrhosis. Approximately 50% of cirrhotic NASH patients with portal hypertension do not have varices when first diagnosed.

To be part of the NAVIGATE Study, you must have a confirmed diagnosis of NASH cirrhosis with no evidence of esophageal varices.